Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review
作者: Daniel E. HillemanBarbara S. WigginsMichael B. Bottorff
作者单位: 1School of Pharmacy and Health Professions, Creighton University, Omaha, NE, USA
2Medical University of South Carolina, Charleston, SC, USA
3Department of Pharmacy Practice, Manchester University, Fort Wayne, IN, USA
刊名: Advances in Therapy, 2020, Vol.37 (suppl 1), pp.656-670
来源数据库: Springer Nature Journal
DOI: 10.1007/s12325-019-01211-1
关键词: Cardiovascular diseaseDietary supplementsDocosahexaenoic acidEicosapentaenoic acidFish oilsHypertriglyceridemiaIcosapent ethylOmega-3-fatty acids
英文摘要: Abstract(#br)Introduction(#br)Currently available omega-3 (OM-3) fatty acid products in the US are either nonprescription dietary supplements (e.g., fish oils) or prescription (Rx) medications. As such, we aimed to describe critical therapeutic differences among the OM-3 fatty acids, focusing on differences between fish oil supplements and Rx OM-3s. Methods(#br)A narrative review of known papers salient to this topic was conducted. Results(#br)Despite the multiple purported clinical benefits, the published evidence for OM-3 dietary supplements is generally insufficient, inconsistent, or negative. Rx OM-3 products are indicated as an adjunct to diet to reduce triglycerides (TG) in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dl). Recently, the Rx eicosapentaenoic acid (EPA)-only...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.125 (2012)

×